Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial.

Summary: Background: Weight loss in children and adolescents with type 2 diabetes (T2D) is associated with improved glycaemic control. Objectives: To assess the effects of liraglutide vs placebo on body mass index (BMI) and weight parameters in children and adolescents with T2D using data from the e...

Descripción completa

Detalles Bibliográficos
Publicado en:Pediatric Obesity Vol. 16; no. 8; pp. 1 - 10
Autores principales: Bensignor, Megan O., Bomberg, Eric M., Bramante, Carolyn T., Divyalasya, T. V. S., Hale, Paula M., Ramesh, Chethana K., Rudser, Kyle D., Kelly, Aaron S.
Formato: research tables/charts randomized controlled trial Journal Article
Publicado: Wiley-Blackwell Aug2021
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=151353350&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 151353350
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        20476302
        ETV7
      jtl: Pediatric Obesity
      issn: 20476302
      maglogo: Y
    pubinfo:
      dt: Aug2021
      vid: 16
      iid: 8
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        151353350
        148936625
        151353350
        151353350
        10.1111/ijpo.12778
        151353350
      ppf: 1
      ppct: 9
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: C
          – @attributes:
              type: P
      tig:
        atl: Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial.
      aug:
        au:
          Bensignor, Megan O.
          Bomberg, Eric M.
          Bramante, Carolyn T.
          Divyalasya, T. V. S.
          Hale, Paula M.
          Ramesh, Chethana K.
          Rudser, Kyle D.
          Kelly, Aaron S.
        affil: Department of Pediatrics, University of Minnesota Medical School, Minneapolis Minnesota, USA
      sug:
        subj:
          Diabetes Mellitus, Type 2 In Infancy and Childhood
          Diabetes Mellitus, Type 2 In Adolescence
          Body Weights and Measures
          Body Mass Index
          Glucagon-Like Peptide-1 Receptor Agonists
          Human
          Male
          Female
          Child
          Adolescence
          Post Hoc Analysis
          Random Assignment
          Randomized Controlled Trials
          Child: 6-12 years
          Adolescent: 13-18 years
          Male
          Female
      ab: Summary: Background: Weight loss in children and adolescents with type 2 diabetes (T2D) is associated with improved glycaemic control. Objectives: To assess the effects of liraglutide vs placebo on body mass index (BMI) and weight parameters in children and adolescents with T2D using data from the ellipse trial (NCT01541215). Methods: The ellipse trial randomized participants (10‐<17 years old, BMI >85th percentile, T2D, glycated haemoglobin [HbA1c] 7.0%‐11.0% [if diet‐ and exercise‐treated] or 6.5% to 11.0% [if treated with metformin, basal insulin or both]) to liraglutide or placebo. This post‐hoc analysis evaluated changes from baseline to weeks 26 and 52 in absolute BMI, percent change in BMI and other weight‐related parameters. Changes were assessed by liraglutide overall (all doses) and liraglutide by dose (0.6, 1.2 and 1.8 mg/day) vs placebo using a pattern mixture model of observed data, with missing observations imputed from each treatment group. Results: In total, 134 participants were included. There were statistically significant differences between groups in certain parameters, including absolute BMI (estimated treatment difference [ETD] –0.89 kg/m2; 95% confidence interval [CI] –1.71,–0.06) and percent change in BMI (ETD –2.73%; 95% CI –5.15,–0.30) at week 52, but none at week 26. Dose‐dependent effects were not observed for liraglutide vs placebo for all BMI/weight parameters. Conclusions: Compared with placebo, liraglutide was associated with statistically significant reductions in BMI/weight parameters at week 52, but not week 26, in children and adolescents with T2D.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N